Background

Cellular senescence originally functions as a defense mechanism to prevent the proliferation of cancer cells. However, the accumulation of senescent cells in the body leads to significant adverse effects. This is because various inflammatory cytokines and chemokines secreted by senescent cells, known as the Senescence-Associated Secretory Phenotype (SASP), damage surrounding normal tissues and induce chronic inflammation. This is identified as a key factor in promoting age-related degenerative diseases such as Alzheimer's disease and osteoarthritis. The medical community has tested numerous drug candidates to reduce the activity of these inflammatory substances, but has not achieved satisfactory results. This is mainly because the approach has been to temporarily inhibit only the downstream pathways of the inflammatory signal, which has exposed the limitation of impairing normal immune function. There was a need to find the fundamental link between the unique metabolic changes that occur during cellular senescence and the regulation of gene expression within the cell nucleus.

Key Findings

An international research team revealed how mitochondrial metabolism in senescent cells triggers epigenetic inflammatory responses. In senescent cells, the expression of the solute carrier family 25 member 1 (SLC25A1) is significantly increased within the mitochondria. This results in the massive release of citrate, which should remain in the mitochondria, into the cytosol, where it is converted into acetyl-CoA by cytosolic enzymes. The accumulated acetyl-CoA is confirmed to enter the nucleus and induce histone acetylation. When histone acetylation occurs, the chromatin structure, which was tightly bound, becomes loosened. In other words, chromatin accessibility increases dramatically, exposing previously closed inflammatory gene loci and activating the transcription process, resulting in the release of SASP. After elucidating this mechanism, the researchers conducted experiments to control the metabolic pathway by administering compounds that inhibit SLC25A1. As a result of drug administration, histone acetylation in the nucleus of senescent cells was noticeably reduced, and the open chromatin structure was re-solidified. This confirmed that the inhibition of inflammatory substance secretion and the regulation of cellular metabolism can be the key to suppressing the inflammatory storm.

Significance and Prospects

This study is significant in that it elucidates the direct interaction pathway in which mitochondrial metabolic substances induce epigenetic changes in the nucleus, leading to age-specific inflammation. Existing cellular senescence removal techniques, such as senolytics, eliminate senescent cells, which carries the risk of causing toxicity to normal cells. In contrast, the newly discovered SLC25A1 blocking method can selectively control the release of harmful inflammatory substances without affecting the survival of senescent cells, which has much less risk of side effects. However, there are still barriers to overcome before entering the new drug development stage. SLC25A1 plays an important role in normal mitochondrial energy metabolism in normal cells, so systemic administration of the drug carries a high risk of causing serious systemic metabolic side effects. Therefore, further research, such as combining it with a targeted delivery system that delivers the drug specifically to senescent cells, will be necessary for clinical application.